StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $2.45 | $2.30 | -6.12% | 0.1M |
| 05-13 | $2.30 | $2.25 | -2.17% | 0.1M |
| 05-14 | $2.33 | $2.27 | -2.58% | 0.1M |
| 05-15 | $2.27 | $2.19 | -3.52% | 0.1M |
| 05-18 | $2.19 | $2.10 | -4.11% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Annual 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $41.46M | $29.05M | $13.89M | $66.38M |
Operating Income | $-7.54M | $-3.47M | $-1.50M | $-7.83M |
Net Income | $-14.24M | $-10.58M | $1.97M | $-13.56M |
EPS (Diluted) | $-1.42 | $-0.89 | $-0.08 | $-2.16 |
Total Assets | $111.69M | $122.00M | $124.99M | $124.18M |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $26.71M | $30.02M | $32.63M | $30.95M |
Free Cash Flow OCF − CapEx | $-1.14M | $3.04M | $-618.00K | $-2.17M |
Shares Outstanding | 10.73M | 10.73M | 9.91M | 8.98M |